Modulation of TXA2 generation of platelets by human lipoproteins. 1990

A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
Department of Pharmacology and Toxicology, Martin Luther University Halle-Wittenberg, GDR.

The lipoprotein (LP) fractions VLDL, LDL, HDL2 and HDL3 were prepared by ultracentrifugation of plasma from healthy volunteers and from patients with coronary heart disease (CHD). We investigated the capacity of platelets from healthy volunteers and patients with atherosclerosis to generate thromboxane A2 (TXA2) during spontaneous clotting of whole blood under the influence of the lipoprotein fractions. In our experiments the serum concentration of TXB2, reflecting the capacity of platelets to generate TXA2 during clotting, depends on several factors: the type of LP fraction used, the blood used for generation of TXA2, and for the same LP fraction whether it was taken from plasma of healthy volunteers or patients with CHD. VLDL prepared from plasma of healthy volunteers inhibited but VLDL prepared from plasma of patients with CHD enhanced the TXA2 formation of platelets from healthy volunteers (p less than 0.05, resp.). LDL from CHD patients inhibited the TXA2 formation of platelets from atherosclerotic patients (p less than 0.01). The HDL subfractions HDL2 and HDL3 from healthy volunteers inhibited TXA2 formation by platelets from healthy volunteers as well as those from atherosclerotic patients (p less than 0.05; p less than 0.01, respectively). HDL2 from patients with CHD inhibited only the TXA2 formation of platelets from healthy volunteers (p less than 0.01), whereas HDL3 from CHD patients inhibited only the TXA2 formation of platelets from atherosclerotic patients (p less than 0.01).

UI MeSH Term Description Entries
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001161 Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. Arterioscleroses
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane

Related Publications

A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
August 1986, Prostaglandins, leukotrienes, and medicine,
A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
February 1988, Biochemical pharmacology,
A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
September 1992, Biochemistry,
A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
November 1986, Thrombosis research,
A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
September 1991, Biochimica et biophysica acta,
A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
August 1984, Blood,
A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
October 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
January 1987, Progress in clinical and biological research,
A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
July 1991, Thrombosis research,
A Beitz, and N A Nikitina, and C Giessler, and J Beitz, and V P Masaev, and N A Perova, and H J Mest
March 1987, The Biochemical journal,
Copied contents to your clipboard!